The protection and efficacy of medicines are of utmost significance, and the CDSCO (Central Medicine Customary Management Organisation) performs a vital function in making certain this by means of common monitoring.
As a part of its routine regulatory surveillance, the CDSCO publishes a month-to-month checklist of Not of Customary High quality (NSQ) and spurious medicine on its portal. In April 2025, the Central Medicine Laboratories recognized 60 drug samples as NSQ, whereas State Medicine Testing Laboratories recognized 136 extra, totaling 196 drug samples that failed to satisfy high quality requirements.
The Identification of drug samples as NSQ is finished based mostly on failure of the drug pattern in a single or the required high quality parameters.
The failure is restricted to the drug merchandise of the batch examined by the Authorities Laboratory, and it doesn’t warrant any issues concerning the different drug merchandise obtainable available in the market.
In April 2025, a severe difficulty got here to gentle in Bihar, the place one drug pattern was discovered to be spurious.
This implies the drug was manufactured with out authorisation and was falsely utilizing one other firm’s model identify. The matter is presently underneath investigation, and applicable motion will likely be taken as per the act and guidelines.
The identification of substandard and spurious medicines is an everyday effort, undertaken in collaboration with state regulators.
The aim is to detect and take away these unsafe medicine from the market, defending public well being and making certain that solely high quality medicines can be found to customers.
This growth highlights the pressing want for strengthened regulatory oversight and public consciousness to make sure the protection and efficacy of medicines obtainable to the general public.
